Corporate Support
Sitemap

Features

Customer Services

Events

Terms of Use

Singapore
Malaysia

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,110.3
-17.4 (-0.56%)

 

  • STI Straits Times Index
    3,110.3
    -17.4 (-0.56%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,609.3
    6.9 (0.43%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,179.3
    130.6 (0.50%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,897.4
    14.0 (0.49%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    20,710.9
    82.9 (0.40%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,255.6
    16.4 (0.26%)
    Index delayed 10 minutes
  • KOR KOSPI
    1,948.3
    -2.7 (-0.14%)
    Index delayed 20 minutes
  • XAO XAO
    6,614.3
    21.3 (0.32%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 728.4M
  • Value: 924.6M
  • Rise: 102
  • Fall: 203
  • Unch: 530

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol

  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
LionGold0.001-
Rex Intl0.083+0.007
YZJ Shipbldg SGD0.915-0.015
ThaiBev0.935+0.005
Mapletree NAC Tr1.310-0.030
SingTel3.250+0.010
TEE Intl0.062-0.004
CapitaMall Trust2.640+0.020
HPH Trust USD0.167-0.010
SPH2.040-0.090

World Indices

World Indices
Name Last Change
Nasdaq 7,991.4 -28.8
HSI 26,179.3 +130.6
HSCEI 10,194.7 +71.8
Jakarta 6,255.6 +16.4
Nikkei 225 20,710.9 +82.9
SSE Comp 2,897.4 +14.0
Shanghai A 3,035.4 +14.7
Shanghai B 264.6 +0.3
PSE Comp 0.0
KOSPI 1,948.3 -2.7

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help

  • Factsheet

  • Print

ILLUMINA INC ILLUMINA
Updated on 22 Aug 2019 (End of trading day)
Last (USD): 288.580 Change: -1.920 High: 291.355 Remarks: -
Change (%): -0.66 Low: 285.710
Open 290.270 Yesterday's Close 290.5
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 449,593 Cumulative Value
 
Click to show Stock Prices chart

Key Statistics

EPS (USD) a 5.61905 Trailing EPS (USD) e 6.38095 NAV (USD) b 29.4694
PE a 51.357 Trailing PE f 45.225 Price / NAV b 9.7925
Dividend (USD) d - Cash In Hand (USD) g 13.2177 Issued & Paid-up Shares c 147,000,000
Dividend Yield (%) d - Price / Cash In Hand g 21.833 Treasury Shares h 45,000,000
Beta - 75 Daysi 0.027 R-Squared - 75 Days(%)i 0.02 Market Cap (M) 42,421.260
Beta - 500 Daysi -0.048 R-Squared - 500 Days (%)i 0.05 Enterprise Value (M) 41,110.260
Piotroski F Score 6 Exchange Code ILMN Par Value ( $ ) n.a.
52 Weeks Volatility (%) 41.32 Free Float (%) -
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 26 Apr 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 12 Feb 2019.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference ILLUMINA INC NASDAQ 42,421.260 51.357 45.225 9.7925 -
Industry Biotechnology NASDAQ 2,237.551 127.732 99.033 5.1707 0.790
Local Peer AMGEN INC NASDAQ 121,991.177 14.533 15.329 11.3017 2.725
Local Peer GILEAD SCIENCES INC NASDAQ 81,331.419 14.910 13.658 3.5962 3.594
Local Peer CELGENE CORP NASDAQ 67,833.601 16.766 12.869 6.7489 -
Local Peer VERTEX PHARMACEUTICAL NASDAQ 47,356.128 22.589 21.380 9.3405 -
Local Peer BIOGEN INC NASDAQ 42,802.771 9.661 8.085 3.3045 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 32,421.031 13.263 15.668 3.3232 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 27,689.792 356.825 20.763 2.7244 -
Local Peer INCYTE CORPORATION NASDAQ 18,401.133 168.058 60.160 8.1885 -
Local Peer EXACT SCIENCES CORP NASDAQ 15,262.397 - - 19.9371 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 13,890.436 - - 4.6912 -
Local Peer SEATTLE GENETICS INC NASDAQ 13,232.105 - - 10.4040 -
Local Peer IONIS PHARMACEUTICALS INC NASDAQ 9,532.925 34.431 23.709 7.5099 -
Other Local Peers ALNYLAM PHARMACEUTICALS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BIO-TECHNE CORP (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), EXELIXIS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), REPLIGEN CORP (NASDAQ), MODERNA INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), FIBROGEN INC (NASDAQ), ALKERMES PLC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), TILRAY INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), GENOMIC HEALTH INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), XENCOR INC (NASDAQ), NATERA INC (NASDAQ), UNIQURE N.V. (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), REGENXBIO INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), VERACYTE INC (NASDAQ), EPIZYME INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), OPKO HEALTH INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), OMEROS CORP (NASDAQ), INTREXON CORP (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ARVINAS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), CYTOKINETICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), ALDER BIOPHARMACEUTICALS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), MACROGENICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), NEXTCURE INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), CORTEXYME INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), PERSONALIS INC (NASDAQ), AVROBIO INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), RETROPHIN INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), SYNTHORX INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), DERMIRA INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), SINOVAC BIOTECH (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), MERUS B V (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), AGENUS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), RESTORBIO INC (NASDAQ), MEDICINOVA INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), XBIOTECH INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), PDL BIOPHARMA INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), RECRO PHARMA INC (NASDAQ), GERON CORP (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), COMPUGEN (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), CHIASMA INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), ARDELYX INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), KAMADA (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), MANNKIND CORPORATION (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ATHERSYS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), AFFIMED N V (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), NOVAVAX INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), GLYCOMIMETICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), CHIMERIX INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), IMV INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), NANTKWEST INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), SESEN BIO INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), TOCAGEN INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), VERASTEM INC (NASDAQ), SYNLOGIC INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), SAVARA INC (NASDAQ), EDAP TMS S.A. SPON ADS EACH REPR 1 ORD SHARE (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), VACCINEX INC (NASDAQ), TREVENA INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), ORGENESIS INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), OTONOMY INC (NASDAQ), EQUILLIUM INC (NASDAQ), CURIS INC (NASDAQ), ARAVIVE INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), COHBAR INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), INMUNE BIO INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), IMMUTEP LTD SPON ADR EACH REP 100 ORD SHS (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), VERMILLION INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), IVERIC BIO INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), FORWARD PHARMA AS SPON ADR EACH REP 2 ORD SHS (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), EVOGENE LTD (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), BIOCARDIA INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), ZAFGEN INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), SENESTECH INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), BIOCEPT INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), SOLIGENIX INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), HISTOGENICS CORP (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), VICAL INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), FIBROCELL SCIENCE INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), PRECIPIO INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), TROVAGENE INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), NOVELION THERAPEUTICS INC (NASDAQ), ATYR PHARMA INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), VAXART INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), BENITEC BIOPHARMA LTD SPON ADR EA REPR 20 ORD (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), ADVAXIS INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), PROTEON THERAPEUTICS INC (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), OPGEN INC (NASDAQ), NEURALSTEM INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADR EACH REP 20 ORD SHS (NASDAQ)
Global Peer AMGEN-T HKEx 599,701.000 9.116 9.612 7.1115 4.345
Global Peer CSL ASX 108,005.681 40.257 40.257 14.4332 1.124
Global Peer AGILENT TECHNOLOGIES INC NYSE 22,669.338 71.739 21.147 4.7755 0.836
Global Peer SINO BIOPHARM HKEx 135,076.224 12.606 12.940 3.8969 0.681
Global Peer WUXI BIO HKEx 105,284.288 140.960 110.199 10.8378 -
Global Peer BEIGENE HKEx 68,714.455 - - 5.6603 -
Global Peer Lonza SGX 5,937.453 7.663 9.330 0.6935 4.766
Global Peer GENSCRIPT BIO HKEx 33,218.258 199.776 199.771 8.8637 -
Global Peer 3SBIO HKEx 31,632.750 20.911 36.298 - -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,146.560 34.235 - 2.1707 -
Other Global Peers FRONTAGE (HKEx), VIVA BIOTECH (HKEx), POLYNOVO LIMITED (ASX), HAOHAI BIOTEC (HKEx), MYOVANT SCIENCES LTD (NYSE), ASCLETIS-B (HKEx), AVITA MEDICAL LTD (ASX), MESOBLAST LTD (ASX), CKLIFE SCIENCES (HKEx), ESSEX BIO-TECH (HKEx), NEXT SCIENCE LTD (ASX), KADMON HLDGS INC (NYSE), STARPHARMA HOLDINGS LIMITED (ASX), ARCUS BIOSCIENCES INC (NYSE), LEE'S PHARM (HKEx), TELIX PHARMACEUTIC (ASX), DPHARMA (Bursa), 22ND CENTURY GROUP INC (NYSE American), PFENEX INC (NYSE American), ENZO BIOCHEM INC (NYSE), LINEAGE CELL THERAPEUTICS INC (NYSE American), PALATIN TECHNOLOGIES INC (NYSE American), STANDARD DIVERSIFIED INC (NYSE American), UNI-BIO GROUP (HKEx), BBI LIFE SCI (HKEx), CYNATA THERAPEUTICS LTD (ASX), NEUREN PHARMACEUTICALS LTD (ASX), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), PORT (SET), CEL-SCI CORP (NYSE American), IBIO INC (NYSE American), RESAPP HEALTH LIMITED (ASX), PHYLOGICA LIMITED (ASX), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), IMMUTEP LTD (ASX), HEMISPHERX BIOPHARMA INC (NYSE American), IMUGENE LIMITED (ASX), CT ENTERPRISE (HKEx), SYNTHETIC BIOLOGICS INC (NYSE American), REGENT PACIFIC (HKEx), ARMATA PHARMACEUTICALS INC (NYSE American), ORTHOCELL LIMITED (ASX), ZELDA THERAPEUTICS LTD (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), BIOTRON (ASX), RHINOMED LIMITED (ASX), ONCOSIL MEDICAL LIMITED (ASX), INVEX THERAPEUTICS LTD NPV (ASX), EXTRAWELL PHAR (HKEx), BIOSINO BIO-TEC (HKEx), ORAGENICS INC (NYSE American), MEMPHASYS LTD (ASX), ISORAY INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), PATRYS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), KAZIA THERAPEUTICS LIMITED (ASX), PROTEOMICS INTL LABORATORIES LTD (ASX), REGENEUS LTD (ASX), ANTEO DIAGNOSTICS LIMITED (ASX), BIONOMICS LTD (ASX), ADALTA LTD (ASX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), NANOVIRICIDES INC (NYSE American), Suntar Eco-City^ (SGX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), CELLMID LIMITED (ASX), IMMURON LIMITED (ASX), GENERA BIOSYSTEMS LIMITED (ASX), HOLISTA COLLTECH LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), BIOXYNE LIMITED (ASX), GENETIC TECHNOLOGIES (ASX), LIVING CELL TECHNOLOGIES (ASX), HAO WEN HLDGS (HKEx), BENITEC BIOPHARMA LTD (ASX), ANATARA LIFESCIENCES LTD (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ACTINOGEN MEDICAL LTD (ASX), MGRC (Bursa), MEGASUN (Bursa), CCP TECHNOLOGIES LTD (ASX), QT Vascular (SGX), TBG DIAGNOSTICS LTD (ASX), NANOLLOSE LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), BPH ENERGY LIMITED (ASX), NOVITA HEALTHCARE LTD (ASX), MEDIBIO LIMITED (ASX), AMPLIA THERAPEUTICS LTD (ASX), ALCHEMIA LIMITED (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+2.410
+0.84 %
10 Days --5.420
-1.84 %
20 Days --12.320
-4.09 %
Medium Term Return 3 Months --23.870
-7.64 %
6 Months --12.480
-4.15 %
1 Year --52.020
-15.27 %
Long Term Return 2 Years -+96.390
+50.15 %
3 Years -+116.370
+67.57 %
5 Years -+109.220
+60.89 %
Annualised Return Annualised --
+9.98 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 268.620 - 380.760 Change From 1 Year Low +19.960 % Change From 1 Year Low (%) +7.43
Change From 1 Year High -92.180 % Change From 1 Year High (%) -24.21
2 Years Range 191.060 - 380.760 Change From 2 Years Low +97.520 % Change From 2 Years Low (%) +51.04
Change From 2 Years High -92.180 % Change From 2 Years High (%) -24.21
5 Years Range 119.370 - 380.760 Change From 5 Years Low +169.210 % Change From 5 Years Low (%) +141.75
Change From 5 Years High -92.180 % Change From 5 Years High (%) -24.21
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Illumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE). The Core Illumina segments serve customers in the research, clinical and applied markets, and enable the adoption of genomic solutions. The Consolidated VIE segment includes activities of GRAIL and Helix. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Historical Price Data

Date Open High Low Close Volume VWAP
22 Aug 2019 290.270 291.355 285.710 288.580 449,593 -
21 Aug 2019 285.540 290.630 284.710 290.500 505,599 -
20 Aug 2019 288.650 290.000 284.510 284.650 621,607 -
19 Aug 2019 290.000 290.000 286.590 288.650 715,454 -
16 Aug 2019 288.170 291.355 285.490 286.170 913,642 -
15 Aug 2019 286.810 287.420 282.410 284.770 715,518 -
14 Aug 2019 288.360 289.450 284.144 285.070 1,028,739 -
13 Aug 2019 289.530 297.880 288.010 293.990 821,277 -
12 Aug 2019 292.090 294.100 288.730 290.340 746,943 -
09 Aug 2019 298.540 299.400 292.360 294.000 829,634 -
08 Aug 2019 293.090 298.720 291.400 298.440 808,742 -
07 Aug 2019 290.070 293.770 285.590 292.870 803,578 -
06 Aug 2019 291.340 292.450 285.370 291.940 988,607 -
05 Aug 2019 292.750 294.660 286.760 289.060 1,292,192 -
02 Aug 2019 301.000 301.000 292.580 297.380 1,027,137 -
01 Aug 2019 300.000 306.070 298.630 301.660 1,244,959 -
31 Jul 2019 300.760 303.935 296.400 299.380 1,743,791 -
30 Jul 2019 298.860 304.000 294.830 299.960 2,353,724 -
29 Jul 2019 301.340 305.300 298.880 304.410 1,112,901 -
26 Jul 2019 300.000 302.980 296.080 300.900 909,235 -
25 Jul 2019 304.730 304.730 297.920 298.600 830,295 -
24 Jul 2019 304.000 306.930 301.970 304.010 928,785 -
Summary
Current 2 Weeks
(09 Aug 2019 to 22 Aug 2019)		 298.540 299.400 282.410 288.580 7,348,006 -
Previous 2 Weeks
(26 Jul 2019 to 08 Aug 2019)		 300.000 302.980 282.410 298.440 12,284,866 -
4 Weeks from
(27 Jun 2019 to 25 Jul 2019)		 358.940 359.165 282.410 298.600 32,088,732 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.